Elsevier, Acta Haematologica Polonica, 1(43), p. 7-47, 2012
DOI: 10.1016/s0001-5814(12)31003-7
Full text: Download
New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtain therapeutic responses in the majority of patients. Therapeutic regimens based on thalidomide and on bortezomib are recommended to the therapy as well of patients being candidates to high dose therapy and autologous stem cell transplantation as unfit to such procedure. In relapsed/refractory patients regimens based on lenalidomide are recommended. An integral part of MM therapy is maintenance therapy and supportive care. In this article we described also therapeutic recommendation for other plasmocytic dyscrasia. © by Polskie Towarzystwo Hematologów i Transfuzjologów i Instytut Hematologii i Transfuzjologii.